tiprankstipranks
Advertisement
Advertisement
Legend Biotech price target raised to $64 from $62 at RBC Capital
PremiumThe FlyLegend Biotech price target raised to $64 from $62 at RBC Capital
18d ago
Legend Biotech’s Earnings Call Highlights CARVYKTI Surge
Premium
Company Announcements
Legend Biotech’s Earnings Call Highlights CARVYKTI Surge
18d ago
Legend Biotech reports Q1 EPS (3c), consensus (17c)
Premium
The Fly
Legend Biotech reports Q1 EPS (3c), consensus (17c)
19d ago
Legend Biotech price target lowered to $49 from $50 at Morgan Stanley
PremiumThe FlyLegend Biotech price target lowered to $49 from $50 at Morgan Stanley
3M ago
Legend Biotech price target lowered to $62 from $66 at RBC Capital
Premium
The Fly
Legend Biotech price target lowered to $62 from $66 at RBC Capital
3M ago
Legend Biotech Posts 2025 CARVYKTI Profitability and Tops 10,000 Patients Treated
Premium
Company Announcements
Legend Biotech Posts 2025 CARVYKTI Profitability and Tops 10,000 Patients Treated
3M ago
Legend Biotech: Undervalued BCMA CAR-T Leader with Lower Commercial Risk and DCF-Supported Upside to $50 Target
PremiumRatingsLegend Biotech: Undervalued BCMA CAR-T Leader with Lower Commercial Risk and DCF-Supported Upside to $50 Target
3M ago
Legend Biotech rises 16.6%
Premium
The Fly
Legend Biotech rises 16.6%
3M ago
Legend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn
Premium
The Fly
Legend Biotech downgraded to Neutral from Buy at Rothschild & Co Redburn
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100